Publications by authors named "J G Baird"

Patients with large B-cell lymphoma (LBCL) progressing after anti-CD19 CAR T-cell (CAR19) therapy have poor outcomes. Subsequent CAR T-cell therapy shows promise, but the impact of residual CAR19 and early relapse remains unclear. We evaluated 37 CAR19-refractory LBCL patients who received anti-CD22 CAR T-cell (CAR22) in a phase 1b trial (NCT04088890).

View Article and Find Full Text PDF

The uniqueness in each person's cancer cells and variation in immune infiltrates means that each tumor represents a unique problem, but therapeutic targets can be found among their shared features. Radiation therapy alters the interaction between the cancer cells and the stroma through release of innate adjuvants. The extranuclear DNA that can result from radiation damage of cells can result in production of the second messenger cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) by cyclic GMP-AMP synthase (cGAS).

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed the effectiveness of two types of ivermectin in killing wild-caught Anopheles mosquitoes in cattle and buffalo on Sumba Island, Indonesia, finding cattle had higher blood levels of the drug.
  • Nine species of Anopheles mosquitoes were tested for susceptibility to ivermectin, with varying degrees of lethality, revealing that long-lasting ivermectin outperformed the standard formulation, especially in cattle.
  • Buffalo were found to attract mosquitoes more than cattle, horses, and humans, indicating they might need higher doses of long-lasting ivermectin to match the effectiveness seen in cattle, highlighting the potential of ivermectin as a livestock treatment for malaria control in Southeast Asia.
View Article and Find Full Text PDF

Local government is well placed to provide leadership for the national ambition in England to halve childhood obesity by 2030 and has delegated authority for many policies thought necessary for effective action. However, with currently constrained local government finances, resources may not be prioritized for the wide range of policies and interventions necessary. Thus, local political commitment is vital for directing local government investment to tackle the issue.

View Article and Find Full Text PDF
Article Synopsis
  • - Outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) are generally poor; however, the FDA approved Loncastuximab-teserine (Lonca) based on the LOTIS-2 trial results for those who have undergone at least two prior treatments.
  • - A retrospective study analyzed 187 patients from 21 US centers treated with Lonca, revealing a complete response rate of 14% and an overall response rate of 32%, indicating lower efficacy in a real-world setting compared to the original trial.
  • - Patients in this study had higher risk features, including bulky disease and high-grade B-cell histology, leading to poorer median event-free survival (2.1 months
View Article and Find Full Text PDF